Predictors of smoking cessation medication use among nonobese and obese smokers

Mo Yang, Hemalkumar Mehta, Debajyoti Bhowmik, Ekere James Essien, Susan M. Abughosh

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The objective of this study was to identify and compare the predictors of smoking cessation medication use among obese and nonobese adult smokers. A retrospective cross-sectional study was conducted using the Medical Expenditure Panel Survey (MEPS) data (2008-2009). The study participants included smokers aged 18 years and older who self-reported their smoking status as smoker. The outcome variable was utilization of any Food and Drug Administration approved smoking cessation medication (varenicline, bupropion, and nicotine replacement therapy). Multivariable logistic regression analyses were conducted. A total of 82.20 million (weighted sample size for two years) adult smokers were included; of which nearly 30% were obese-smokers. The use of smoking cessation medication was 2.66% and 5.17% among nonobese and obese smokers, respectively. Multivariable logistic regression results showed that race/ethnicity, health insurance coverage, prescription insurance coverage, usual source of health care, urban residence, region, Charlson comorbidity index, and instrumental activities of daily living (IADL), were significant predictors of using smoking cessation medications. The overall smoking cessation medication use rate was low implying limited compliance to guideline. Predictors identified in this study should be taken into consideration in health promotion programs that are designed to optimize the utilization of these smoking cessation medications.

Original languageEnglish (US)
Pages (from-to)752-761
Number of pages10
JournalSubstance Use and Misuse
Volume49
Issue number6
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Smoking Cessation
smoking
medication
Insurance Coverage
insurance coverage
Pharmaceutical Services Insurance
Logistic Models
Bupropion
logistics
utilization
regression
United States Food and Drug Administration
Health Insurance
Activities of Daily Living
Health Expenditures
Health Promotion
Nicotine
Sample Size
comorbidity
Comorbidity

Keywords

  • Medical expenditure panel survey (MEPS) data
  • Medication use
  • Obesity
  • Risk factors
  • Smoking cessation

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Public Health, Environmental and Occupational Health
  • Health(social science)
  • Medicine (miscellaneous)
  • Medicine(all)

Cite this

Predictors of smoking cessation medication use among nonobese and obese smokers. / Yang, Mo; Mehta, Hemalkumar; Bhowmik, Debajyoti; Essien, Ekere James; Abughosh, Susan M.

In: Substance Use and Misuse, Vol. 49, No. 6, 2014, p. 752-761.

Research output: Contribution to journalArticle

Yang, M, Mehta, H, Bhowmik, D, Essien, EJ & Abughosh, SM 2014, 'Predictors of smoking cessation medication use among nonobese and obese smokers', Substance Use and Misuse, vol. 49, no. 6, pp. 752-761. https://doi.org/10.3109/10826084.2014.880121
Yang, Mo ; Mehta, Hemalkumar ; Bhowmik, Debajyoti ; Essien, Ekere James ; Abughosh, Susan M. / Predictors of smoking cessation medication use among nonobese and obese smokers. In: Substance Use and Misuse. 2014 ; Vol. 49, No. 6. pp. 752-761.
@article{33a4cc3db8cf4d65801079b62d6f8d91,
title = "Predictors of smoking cessation medication use among nonobese and obese smokers",
abstract = "The objective of this study was to identify and compare the predictors of smoking cessation medication use among obese and nonobese adult smokers. A retrospective cross-sectional study was conducted using the Medical Expenditure Panel Survey (MEPS) data (2008-2009). The study participants included smokers aged 18 years and older who self-reported their smoking status as smoker. The outcome variable was utilization of any Food and Drug Administration approved smoking cessation medication (varenicline, bupropion, and nicotine replacement therapy). Multivariable logistic regression analyses were conducted. A total of 82.20 million (weighted sample size for two years) adult smokers were included; of which nearly 30{\%} were obese-smokers. The use of smoking cessation medication was 2.66{\%} and 5.17{\%} among nonobese and obese smokers, respectively. Multivariable logistic regression results showed that race/ethnicity, health insurance coverage, prescription insurance coverage, usual source of health care, urban residence, region, Charlson comorbidity index, and instrumental activities of daily living (IADL), were significant predictors of using smoking cessation medications. The overall smoking cessation medication use rate was low implying limited compliance to guideline. Predictors identified in this study should be taken into consideration in health promotion programs that are designed to optimize the utilization of these smoking cessation medications.",
keywords = "Medical expenditure panel survey (MEPS) data, Medication use, Obesity, Risk factors, Smoking cessation",
author = "Mo Yang and Hemalkumar Mehta and Debajyoti Bhowmik and Essien, {Ekere James} and Abughosh, {Susan M.}",
year = "2014",
doi = "10.3109/10826084.2014.880121",
language = "English (US)",
volume = "49",
pages = "752--761",
journal = "Substance Use and Misuse",
issn = "1082-6084",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Predictors of smoking cessation medication use among nonobese and obese smokers

AU - Yang, Mo

AU - Mehta, Hemalkumar

AU - Bhowmik, Debajyoti

AU - Essien, Ekere James

AU - Abughosh, Susan M.

PY - 2014

Y1 - 2014

N2 - The objective of this study was to identify and compare the predictors of smoking cessation medication use among obese and nonobese adult smokers. A retrospective cross-sectional study was conducted using the Medical Expenditure Panel Survey (MEPS) data (2008-2009). The study participants included smokers aged 18 years and older who self-reported their smoking status as smoker. The outcome variable was utilization of any Food and Drug Administration approved smoking cessation medication (varenicline, bupropion, and nicotine replacement therapy). Multivariable logistic regression analyses were conducted. A total of 82.20 million (weighted sample size for two years) adult smokers were included; of which nearly 30% were obese-smokers. The use of smoking cessation medication was 2.66% and 5.17% among nonobese and obese smokers, respectively. Multivariable logistic regression results showed that race/ethnicity, health insurance coverage, prescription insurance coverage, usual source of health care, urban residence, region, Charlson comorbidity index, and instrumental activities of daily living (IADL), were significant predictors of using smoking cessation medications. The overall smoking cessation medication use rate was low implying limited compliance to guideline. Predictors identified in this study should be taken into consideration in health promotion programs that are designed to optimize the utilization of these smoking cessation medications.

AB - The objective of this study was to identify and compare the predictors of smoking cessation medication use among obese and nonobese adult smokers. A retrospective cross-sectional study was conducted using the Medical Expenditure Panel Survey (MEPS) data (2008-2009). The study participants included smokers aged 18 years and older who self-reported their smoking status as smoker. The outcome variable was utilization of any Food and Drug Administration approved smoking cessation medication (varenicline, bupropion, and nicotine replacement therapy). Multivariable logistic regression analyses were conducted. A total of 82.20 million (weighted sample size for two years) adult smokers were included; of which nearly 30% were obese-smokers. The use of smoking cessation medication was 2.66% and 5.17% among nonobese and obese smokers, respectively. Multivariable logistic regression results showed that race/ethnicity, health insurance coverage, prescription insurance coverage, usual source of health care, urban residence, region, Charlson comorbidity index, and instrumental activities of daily living (IADL), were significant predictors of using smoking cessation medications. The overall smoking cessation medication use rate was low implying limited compliance to guideline. Predictors identified in this study should be taken into consideration in health promotion programs that are designed to optimize the utilization of these smoking cessation medications.

KW - Medical expenditure panel survey (MEPS) data

KW - Medication use

KW - Obesity

KW - Risk factors

KW - Smoking cessation

UR - http://www.scopus.com/inward/record.url?scp=84897540656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897540656&partnerID=8YFLogxK

U2 - 10.3109/10826084.2014.880121

DO - 10.3109/10826084.2014.880121

M3 - Article

C2 - 24494623

AN - SCOPUS:84897540656

VL - 49

SP - 752

EP - 761

JO - Substance Use and Misuse

JF - Substance Use and Misuse

SN - 1082-6084

IS - 6

ER -